Alumis Inc. Common Stock (ALMS) - Stock Analysis
Last updated: Mar 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Alumis (ALMS) gained 100%+ after positive Phase 3 psoriasis trial results and raised cash position, supported by strong technical momentum, positioning as a hot idea with near-term FDA submission catalyst.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High liquidity ⢠Severe cash burn ⢠Significant dilution ALMS combines strong liquidity and low leverage with steep cash burn, deep operating losses, negligible revenue, and marked share dilution, threatening near-term profitability and perâshare value.
Price Behavior
Key Price Behavior Insights: ⢠Midâ$26s support ⢠Highâ29s resistance ⢠Elevated intraperiod volatility Support Level: $26.19â$26.59 Resistance Level: $29.70â$29.98 (bullish break > $30.00) Over the last month ALMS traded flat-to-mildly up after repeatedly finding support in the mid-$26s but failed to sustain lateâFebruary highs near $29.7â$29.98, leaving resistance in the highâ29s and a ~14% intraperiod range.
Sentiment & News
Key News Insights: ⢠Significant selldown ⢠New stake added ⢠CEO outreach Alumis experienced mixed institutional activityâCredit Industriel ET Commercial cut its stake by 140,000 shares (36.2%) while AXQ Capital opened a ~19,452-share position, both reported in Q3 filings, and CEO Martin Babler will speak at the Leerink conference on March 9.
AI Summary
ALMS has shifted from a preclinical optionality story to a near-term, binary regulatory/commercial bet where Phase 3 success and a timely H2 2026 NDA will determine whether the company's strong efficacy data and replenished (but highly dilutive) capital base translate into meaningful upside or force further equity financing; investors should actively monitor NDA submission quality, FDA feedback, and partnering/funding discussions as the most value-defining catalysts. The principal risk is cash burn-driven dilution and commercialization execution (pricing, payer uptake, and scaling) that could erode value even with approval.
Description
Alumis Inc. is a clinical-stage biopharmaceutical company developing allosteric TYK2 inhibitors to treat autoimmune conditions. Its lead program, ESK-001, is in clinical development for dermatologic, systemic and ocular autoimmune disorders, while A-005 is a CNS-penetrant candidate intended for neuroinflammatory and neurodegenerative indications. The company was incorporated in 2021, renamed from Esker Therapeutics in January 2022, and is based in South San Francisco, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 29 | Feb 5 | ALMS | Alumis Inc. Common Stock | Alumis (ALMS) gained 100%+ after positive Phase 3 psoriasis trial results and raised cash position, supported by strong technical momentum, positioning as a hot idea with near-term FDA submission catalyst. | Closed | -1.9% |
| Jan 7 | Jan 14 | ALMS | Alumis Inc. Common Stock | Selected due to recent Phase 3 clinical trial success on 2026-01-07 driving strong near-term momentum and technical breakout; event-driven upside expected from FDA submission and regulatory catalysts. | Closed | +35.8% |